Zephyrnet Logo

Tag: Presentations

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.

In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.

In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

Eisai's Focus on Cancer

Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

A Deep Look Into 13 Data Scientist Roles and Their Responsibilities

Any modern company of any significant size around the world has a data science department, and a data engineer at one company might have the same responsibilities as a marketing scientist at another company. Data science jobs are not well-labeled, so make sure to cast a wide net.

Intel and Nvidia just dunked on Apple’s M1 Max. Should you believe the hype?

Let’s Play! Raising the Stakes for Threat Modeling With Card Games

On a recent Friday night, three security experts got together to play custom games that explore attack risks in an engaging way.

How Bitcoin 2021 Redefined The Importance Of In-Person Celebration

The biggest Bitcoin event in history welcomed more than 12,000 enthusiasts to celebrate together in real life, proving that this decentralized, open-source software project is a cultural force to be reckoned with.

Needham & Company to Host the 24th Annual Needham Growth Conference, January 10-14, 2022

Over 550 Leading Growth Companies are scheduled to Participate Virtually NEW YORK–(BUSINESS WIRE)–Needham & Company will be holding its 24th Annual Needham Growth Conference (“NGC”) on January 10-14, 2022. Needham & Company’s flagship conference is one of the largest events for growth stock investing in the country, with a record number of over 550 presenting […]

International Conference on “MSMEs: Legislative and Regulatory Challenges” (UNCITRAL and Indian Perspective)

The Conference invites proposals for presentations from interested students, academicians, practitioners, professionals, and experts. Themes for the Conference : MSMEs: Legislative and Regulatory Framework MSMEs [...]

CJ’s five favorite games of 2021 that Destructoid didn’t review

Because you can’t review them all Anybody who says that 2021 was a lackluster year for gaming must have been...

The post CJ’s five favorite games of 2021 that Destructoid didn’t review appeared first on Destructoid.

Event: Insuring Cannabis Summit Presented By The Insurance Journal

Overview Access to The Insuring Cannabis Summit on-demand presentations is here! Get the information you need whether you’re well-established in the business of insuring cannabis or you only want to dabble in the space. Hear from all of our experts on cannabis and insurance tackling the relevant questions and outlining the poignant issues – the […]

Deliver a Killer Presentation in Data Science Interviews

How to present yourself as a strong candidate in interview presentations.

DISCO to Present at Needham Growth Conference

AUSTIN, Texas–(BUSINESS WIRE)–Legal technology leader CS Disco, Inc. (“DISCO”) (NYSE: LAW) today announced that its Chief Executive Officer, Kiwi Camara, and Chief Financial Officer, Michael Lafair, will present at the Needham Growth Conference. Date: Tuesday, January 11, 2022 Time: 2:00 p.m. ET (1:00 p.m. CT) Webcast: Events and Presentations at ir.csdisco.com; an archived replay will […]

The post DISCO to Present at Needham Growth Conference appeared first on Fintech News.

NiftyAgenda Final Lineup Includes 20 Demos, NFT Gallery Showing and Press Conference on Underdogs and Female Empowerment Featuring NFT Platform Banned from CES

LAS VEGAS - January 6, 2022 - CoinAgenda (www.coinagenda.com), the premier global conference series connecting blockchain and cryptocurrency investors with startups since 2014, today is launching its newest NFT-focused event, NiftyAgenda, with an exclusive launch party on January 6 from 5-11 pm in Las Vegas, following CES®, the largest Consumer Electronics Show in the world. All NFT creators, innovators, buyers, and media are invited. 


NFT mainstream popularity exploded in 2021, starting in Q1 when Beeple's Everydays: The First 5000s, sold in auction for $69 million, bringing rise for artists to take digital ownership and compensation over their art. With the sales of NFTs expected to exceed $20 billion by the end of 2021, NiftyAgenda will kick off with presentations and a meet-and-greet from the leaders behind the hottest upcoming NFT drops. 


Presenters include: 

Hot Drops, the first inclusive adult NFT marketplace disrupting how creators and fans connect with next-gen content.

Fearless Girl, the iconic statue on Wall Street, which is issuing a series of NFTs to fight lawsuit by a big bank to seize control of her copyrights.

Starter Capital, the leading launchpad, incubator, and investor network for Polygon, Ethereum, Fantom, Avalanche, BSC, which is partnering with the OpenDao initiative to decentralize OpenSea.

NFTY, a blockchain studio and incubator for the next generation of NFT technology.

SDG Exchange, a global sustainability marketplace dedicated to reversing climate change one transaction at a time.

Echo Labs, a space for artists of all kinds to get their voices heard and their distinct point of view and missions noticed.

Icecap, a Blockchain-Based Diamond NFT Marketplace.

RAIR TECH, a blockchain-based digital rights management platform that uses NFTs to gate access to streaming content.

Tradery Capital, an AI-powered asset manager for Coinbase customers.

Pixel Bird, a NFT collection of pixelated birds, the result of the evolution of a group of dinosaurs that lived hundreds of years ago.

Frogland, a hand-drawn series of 10,000 generative NFTs, with each frog being entitled to a LillyPAD, or Personal Access Domain, with Frogland, the central most founding district of the metaverse.

On1 Force, a collection of 7,777 generative side-profile characters with over 100 hand-drawn features fighting for their existence. 

A List Apes, a NFT project featuring a unified community that represents each unique person and makes them feel comfortable with their individuality of character, appearance, and principles.



Following presentations by NFT creators and analysts will be an immersive digital gallery showcasing the NFT creators' newest drops and a concert by Think:X, featuring legendary Pink Floyd sax player, and NFT creator Scott Page, and Jane's Addiction drummer, Stephen Perkins. This all-star line up will perform “Beyond the Wall,” an exploration of the music of Pink Floyd, for a Think Floyd experience. The concert will simultaneously happen with NFT demonstrations and videos in the background, a full bar and heavy hors d'oeuvres. NiftyAgenda is being held at two iconic former celebrity estates ten minutes from the Strip; location details will be given with ticket purchase. Space is limited.


NiftyAgenda tickets are available for $299 and include the meet-and-greet segment, NFT gallery showcase, and Think:X concert. CES accredited media will be allowed in at no cost upon independent verification of credentials.

For more information, please contact contact@coinagenda.com.


ABOUT NIFTYAGENDA

NiftyAgenda brings together NFT creators, innovators, buyers and media. NiftyAgenda is the newest conference from CoinAgenda, which has been producing high-end crypto investor events globally since 2014.


ABOUT COINAGENDA

Now in its eighth year, CoinAgenda is the leading global conference series connecting professional investors, traders, family offices and digital currency funds with top entrepreneurs in the blockchain and cryptocurrency sectors. CoinAgenda is an experience that allows all attendees to meet, mingle, and get to know the leading thought leaders, entrepreneurs and investors in the sector, including memorable parties at unique locations. 


Disclaimer: Consumer Electronics Show”, "CES,” “CES®” and “International CES®” are registered trademarks of the Consumer Electronics Association. NiftyAgenda at CES 2022 is not affiliated with or endorsed by CES or the Consumer Electronics Association.

Latest Intelligence

spot_img
spot_img

Chat with us

Hi there! How can I help you?